Related Experiment Videos
Xq27-28 deletions in prostate carcinoma
Adam S Kibel1, Dennis A Faith, G Steven Bova
1Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA. kibela@msnotes.wustl.edu
Genes, Chromosomes & Cancer
|June 12, 2003
Summary
Genomic deletions at the Xq27-28 locus (HPCX) occur in sporadic prostate cancer. These deletions, found in two patients, suggest a role for the HPCX region in sporadic disease development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Linkage studies identified a prostate cancer susceptibility locus at Xq27-28 (HPCX), accounting for ~16% of hereditary prostate cancer.
- The HPCX region's role in sporadic prostate cancer remained uninvestigated.
Purpose of the Study:
- To investigate genomic alterations, specifically deletions, within the Xq27-28 (HPCX) region in sporadic prostate cancer.
- To determine if the HPCX locus is involved in the development of sporadic prostate tumors.
Main Methods:
- Examined tumor DNA from sporadic prostate cancer patients, cell lines, and xenografts.
- Utilized PCR amplification across 11 loci in the Xq27-28 region for 19 sporadic prostate cancer patients.
- Analyzed multi-sampled metastatic prostate cancer DNA to detect nullizygosity.
Main Results:
- Somatic deletions within the Xq27-28 region were identified in 2 out of 19 sporadic prostate cancer patients.
- In both cases with deletions, all metastatic tumor samples from an individual showed the same reduction to nullizygosity.
- Deletions had breakpoints within a 500-800 kb interval containing FMR1, but the deletions were non-overlapping.
Conclusions:
- Genomic deletions occur within the HPCX locus in a subset of sporadic prostate cancers.
- These findings suggest that the gene(s) at the HPCX locus may play a role in sporadic prostate cancer development.
- Further investigation is warranted to identify the specific gene(s) and their function in sporadic disease.